Rocket


Overview
Financials
News + Filings
Key Docs
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Credit agrmnt [a]
Director departure

American Realty Capital Trust, Inc. (ARCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/11/2019 GN Arcturus Therapeutics to Present at Upcoming Investor Conferences
01/03/2019 GN Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
01/02/2019 GN Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
11/05/2018 GN Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
10/01/2018 GN Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/25/2018 GN Arcturus Therapeutics to Present at October Investor Conferences
09/21/2018 GN Arcturus Therapeutics Expands Management Team
08/29/2018 GN Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company's Independent Auditor
08/27/2018 GN Arcturus Therapeutics to Present at Three Investor Conferences in September
07/23/2018 GN Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
07/20/2018 GN Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018
07/09/2018 GN Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
06/18/2018 GN Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
05/31/2018 GN Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO
05/30/2018 GN Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
05/29/2018 GN Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne
05/23/2018 GN Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D
05/23/2018 GN Arcturus Therapeutics Founder Joseph Payne Calls for an End to Company's Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Date
05/21/2018 GN Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
05/14/2018 GN Arcturus Therapeutics Files Form 20-F
05/14/2018 GN Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members
05/02/2018 GN Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board's Egregious Attempt to Dilute Shareholders
04/23/2018 GN Arcturus Therapeutics Founder Joseph Payne Dismisses Board's Baseless Lawsuit as Desperate Entrenchment Tactic
04/20/2018 GN Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws
04/13/2018 GN Arcturus Therapeutics Founder Joseph Payne Disappointed by Board's Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability
04/08/2018 GN Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders
03/28/2018 GN Arcturus Therapeutics Issues Open Letter to Shareholders
03/27/2018 GN Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders
03/11/2018 GN Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
03/05/2018 GN Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach
02/26/2018 GN Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
02/16/2018 GN Arcturus Therapeutics Comments on Amended 13D Filing
02/12/2018 GN Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
02/06/2018 GN Arcturus Therapeutics Issues Statement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy